Pyxis Oncology (PYXS) Free Cash Flow (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Free Cash Flow data on file, last reported at -$10.4 million in Q4 2025.

• On a quarterly basis, Free Cash Flow rose 45.95% year-over-year to -$10.4 million in Q4 2025; TTM through Dec 2025 was -$63.5 million, a 9.66% decrease from a year earlier, with the FY2025 full-year figure at -$63.5 million, down 9.67% from the prior year.
• Free Cash Flow for Q4 2025 stood at -$10.4 million, up from -$13.3 million in the prior quarter.
• Over the last five years, Free Cash Flow for PYXS reached as high as $2.5 million in Q2 2021 and fell as low as -$29.1 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$16.2 million across 5 years, with a median of -$17.5 million in 2023.
• Across the five-year window, Free Cash Flow slumped 1049.3% in 2022 and surged 80.52% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$12.2 million in 2021, then tumbled by 84.29% to -$22.4 million in 2022, then surged by 60.92% to -$8.8 million in 2023, then tumbled by 120.08% to -$19.3 million in 2024, then surged by 45.95% to -$10.4 million in 2025.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$10.4 million in Q4 2025, -$13.3 million in Q3 2025, and -$17.3 million in Q2 2025.